Literature DB >> 22562786

Analysis of the neutral polysaccharide fraction of MCP and its inhibitory activity on galectin-3.

Xiaoge Gao1, Yuan Zhi, Tao Zhang, Huiting Xue, Xiao Wang, Anthony D Foday, Guihua Tai, Yifa Zhou.   

Abstract

The pH-modified citrus pectin (MCP) has been demonstrated to inhibit galectin-3 in cancer progression. The components and structures of MCP related to this inhibition remained unknown. In this paper, we fractionated MCP on DEAE-cellulose column into a homogenous neutral fraction MCP-N (about 20 kDa) and a pectin mixture fraction MCP-A (wide molecular distribution on Sepharose CL-6B chromatography). Both MCP-N and MCP-A inhibited hemagglutination mediated by galectin-3 with minimum inhibition concentration (MIC) 625 and 0.5 μg/ml, respectively. MCP-N was identified to be a type I arabinogalactan (AG-I) with a main chain of β-1→4-galactan. MCP-N was digested by α-L-arabinofuranosidase to give its main chain structure fraction (M-galactan, around 18 kDa), which was more active than the original molecule, MIC 50 μg/ml. The acidic degradation of M-galactan increased the inhibitory activity, MIC about 5 times lower than M-galactan. These results above showed that the functional motif of the β-1→4-galactan fragment might lie in the terminal residues rather than in the internal region of the chain. Therefore, MCP-N and its degraded products might be developed to new potential galectin-3 inhibitors. This is the first report concerning the fractionation of MCP and its components on galectin-3 inhibition. The information provided in this paper is valuable for screening more active galectin-3 inhibitors from natural polysaccharides.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22562786     DOI: 10.1007/s10719-012-9382-5

Source DB:  PubMed          Journal:  Glycoconj J        ISSN: 0282-0080            Impact factor:   2.916


  23 in total

1.  Modified apple polysaccharide prevents against tumorigenesis in a mouse model of colitis-associated colon cancer: role of galectin-3 and apoptosis in cancer prevention.

Authors:  Yuhua Li; Li Liu; Yinbo Niu; Juan Feng; Yang Sun; Xianghe Kong; Yongchun Chen; Xiaoyan Chen; Hongquan Gan; Shousong Cao; Qibing Mei
Journal:  Eur J Nutr       Date:  2011-04-24       Impact factor: 5.614

2.  Design and synthesis of galectin inhibitors.

Authors:  Pernilla Sörme; Barbro Kahl-Knutsson; Ulf Wellmar; Bengt-Göran Magnusson; Hakon Leffler; Ulf J Nilsson
Journal:  Methods Enzymol       Date:  2003       Impact factor: 1.600

3.  Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin.

Authors:  Pratima Nangia-Makker; Victor Hogan; Yuichiro Honjo; Sara Baccarini; Larry Tait; Robert Bresalier; Avraham Raz
Journal:  J Natl Cancer Inst       Date:  2002-12-18       Impact factor: 13.506

4.  GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death.

Authors:  Matthew J Streetly; Lenushka Maharaj; Simon Joel; Steve A Schey; John G Gribben; Finbarr E Cotter
Journal:  Blood       Date:  2010-02-26       Impact factor: 22.113

5.  Carbohydrate-binding proteins in cancer, and their ligands as therapeutic agents.

Authors:  Pratima Nangia-Makker; Jeffrey Conklin; Victor Hogan; Avraham Raz
Journal:  Trends Mol Med       Date:  2002-04       Impact factor: 11.951

6.  Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium.

Authors:  Vladislav V Glinsky; Gennadi V Glinsky; Olga V Glinskii; Virginia H Huxley; James R Turk; Valeri V Mossine; Susan L Deutscher; Kenneth J Pienta; Thomas P Quinn
Journal:  Cancer Res       Date:  2003-07-01       Impact factor: 12.701

7.  Modulation of the lung colonization of B16-F1 melanoma cells by citrus pectin.

Authors:  D Platt; A Raz
Journal:  J Natl Cancer Inst       Date:  1992-03-18       Impact factor: 13.506

Review 8.  Modified citrus pectin anti-metastatic properties: one bullet, multiple targets.

Authors:  Vladislav V Glinsky; Avraham Raz
Journal:  Carbohydr Res       Date:  2008-09-26       Impact factor: 2.104

9.  Synthetic galectin-3 inhibitor increases metastatic cancer cell sensitivity to taxol-induced apoptosis in vitro and in vivo.

Authors:  Vladislav V Glinsky; Galina Kiriakova; Olga V Glinskii; Valeri V Mossine; Thomas P Mawhinney; James R Turk; Anna B Glinskii; Virginia H Huxley; Janet E Price; Gennadi V Glinsky
Journal:  Neoplasia       Date:  2009-09       Impact factor: 5.715

10.  Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury.

Authors:  Maria Kolatsi-Joannou; Karen L Price; Paul J Winyard; David A Long
Journal:  PLoS One       Date:  2011-04-08       Impact factor: 3.240

View more
  13 in total

1.  The inhibitory effects of a rhamnogalacturonan I (RG-I) domain from ginseng pectin on galectin-3 and its structure-activity relationship.

Authors:  Xiaoge Gao; Yuan Zhi; Lin Sun; Xiaoxia Peng; Tao Zhang; Huiting Xue; Guihua Tai; Yifa Zhou
Journal:  J Biol Chem       Date:  2013-10-07       Impact factor: 5.157

2.  Migration and proliferation of cancer cells in culture are differentially affected by molecular size of modified citrus pectin.

Authors:  Samira Bernardino Ramos do Prado; Tânia Misuzu Shiga; Yosuke Harazono; Victor A Hogan; Avraham Raz; Nicholas C Carpita; João Paulo Fabi
Journal:  Carbohydr Polym       Date:  2019-02-04       Impact factor: 9.381

Review 3.  Anti-cancer activities of pH- or heat-modified pectin.

Authors:  Lionel Leclere; Pierre Van Cutsem; Carine Michiels
Journal:  Front Pharmacol       Date:  2013-10-08       Impact factor: 5.810

Review 4.  Turning-Off Signaling by Siglecs, Selectins, and Galectins: Chemical Inhibition of Glycan-Dependent Interactions in Cancer.

Authors:  Alejandro J Cagnoni; Juan M Pérez Sáez; Gabriel A Rabinovich; Karina V Mariño
Journal:  Front Oncol       Date:  2016-05-13       Impact factor: 6.244

Review 5.  Pleiotropic Effects of Modified Citrus Pectin.

Authors:  Isaac Eliaz; Avraham Raz
Journal:  Nutrients       Date:  2019-11-01       Impact factor: 5.717

6.  Chemoprevention of Low-Molecular-Weight Citrus Pectin (LCP) in Gastrointestinal Cancer Cells.

Authors:  Shi Wang; Pei Li; Sheng-Min Lu; Zhi-Qiang Ling
Journal:  Int J Biol Sci       Date:  2016-04-28       Impact factor: 6.580

7.  Low or No Inhibitory Potency of the Canonical Galectin Carbohydrate-binding Site by Pectins and Galactomannans.

Authors:  John Stegmayr; Adriana Lepur; Barbro Kahl-Knutson; Matilde Aguilar-Moncayo; Anatole A Klyosov; Robert A Field; Stina Oredsson; Ulf J Nilsson; Hakon Leffler
Journal:  J Biol Chem       Date:  2016-04-26       Impact factor: 5.157

Review 8.  Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update.

Authors:  Navin Suthahar; Wouter C Meijers; Herman H W Silljé; Jennifer E Ho; Fu-Tong Liu; Rudolf A de Boer
Journal:  Theranostics       Date:  2018-01-01       Impact factor: 11.556

9.  Modified citrus pectin inhibits galectin-3 function to reduce atherosclerotic lesions in apoE-deficient mice.

Authors:  Yonggang Lu; Mingming Zhang; Pei Zhao; Min Jia; Bing Liu; Qian Jia; Jun Guo; Lin Dou; Jian Li
Journal:  Mol Med Rep       Date:  2017-05-29       Impact factor: 2.952

10.  Galectin 3 inhibition attenuates renal injury progression in cisplatin-induced nephrotoxicity.

Authors:  Hong-Yan Li; Shen Yang; Jing-Chun Li; Jian-Xun Feng
Journal:  Biosci Rep       Date:  2018-12-18       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.